---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-429423"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2026-10-23T10:36:06+00:00"
generated_at: "2026-10-23T10:40:06.212171+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tango's vopimetostat+daraxonrasib shows 82% ORR in 2L/3L PDAC; Phase 3 planned, workforce cut 14%

## Summary
- Phase 1/2: 82% ORR (18/22) in 2L/3L MTAP-deleted/RAS-mutant PDAC; median PFS not reached, 88% 9-month PFS, 100% DCR at Aug 20, 2026 cutoff.
- Dose level 1 vopimetostat 200 mg + daraxonrasib 100 mg daily well tolerated: no DLTs, no Grade 4/5 TRAEs, Grade 3 TRAEs 40%; dose level 2 had 3 DLTs in 2 patients.
- FDA-aligned Phase 3 in front-line MTAP-deleted PDAC to randomize 1:1 vopimetostat+daraxonrasib vs standard chemotherapy, dual primary endpoints ORR and PFS, starting 1H 2027.
- Zoldonrasib combo in MTAP-deleted/KRAS G12D PDAC: 54% ORR (19/35), 61% 9-month PFS, 97% DCR; NSCLC daraxonrasib combo 80% ORR (4/5).
- Board approved Oct 22 strategic reprioritization: focus on PRMT5/vopimetostat/TNG456, halt certain preclinical work, cut workforce ~14%, mostly research.

## SEC filing metadata
- accession: 0001193125-26-429423
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2026-10-23T10:36:06+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312526429423/0001193125-26-429423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312526429423/d151613d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-429423
- JSON: https://secwatch.observer/filing/0001193125-26-429423.json
- Plain text: https://secwatch.observer/filing/0001193125-26-429423.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.